Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study-Reference-Cited by-同舟云学术

Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study

Published:2015-03-30 Issue:5 Volume:29 Page:439-446
ISSN:0902-0063
Container-title:Clinical Transplantation
language:en
Short-container-title:Clin Transplant

Author:

Bachelet Thomas¹²³,Nodimar Celine¹³,Taupin Jean-Luc²³⁴,Lepreux Sebastien²³⁵,Moreau Karine¹³,Morel Delphine¹³,Guidicelli Gwendaline²³⁴,Couzi Lionel¹²³,Merville Pierre¹²³

Affiliation:

1. Unité de Transplantation; Service de Néphrologie, Transplantation, Dialyse; CHU de Bordeaux; Bordeaux France

2. UMR 5164; CNRS; Bordeaux France

3. Université de Bordeaux; Bordeaux France

4. Laboratoire d'Immunologie et Immunogénétique; CHU Bordeaux; Bordeaux France

5. Laboratoire d'Anatomie Pathologique; CHU Bordeaux; Bordeaux France

Publisher

Wiley

Subject

Transplantation

Reference29 articles.

1. Identifying specific causes of kidney allograft loss;El-Zoghby;Am J Transplant,2009

2. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions;Haas;Am J Transplant,2014

3. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies;Wavamunno;Am J Transplant,2007

4. Transplant glomerulopathy;Cosio;Am J Transplant,2008

5. Transplant glomerulopathy: subclinical incidence and association with alloantibody;Gloor;Am J Transplant,2007

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study);Trials;2024-03-22

2. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design;Trials;2022-12-22

3. A comparison of methods of plasmapheresis for the treatment of late antibody mediated rejection in kidney transplant recipients;Therapeutic Apheresis and Dialysis;2022-10-14

4. Prognosis and Treatment for Active and Chronic Antibody-Mediated Rejection in Renal Transplant Recipients; Single Center Experience;Transplantation Proceedings;2022-09

5. Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials;Expert Opinion on Emerging Drugs;2022-04-03